Suchergebnisse - "Pipe, Steven"

PubPharm (194)

11

Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants : Results from the phase III HOPE‐B trial 2 years after gene therapy

enthalten in: Haemophilia | 2024

von Itzler, R. | Buckner, T. | Leebeek, F. | +5

12

Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1

enthalten in: Journal of thrombosis and haemostasis : JTH | 2023

von O'Mahony, B. | Dunn, A. | Leavitt, A. | +23

13

Delivery of gene therapy in haemophilia treatment centres in the United States : Practical aspects of preparedness and implementation

enthalten in: Haemophilia : the official journal of the World Federation of Hemophilia | 2023

von Pipe, S. | Douglas, K. | Hwang, N. | +3

14

Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy

enthalten in: Blood advances | 2023

von von Drygalski, A. | Gomez, E. | Giermasz, A. | +11

15

Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B

enthalten in: Blood advances | 2023

von Schmidt, M. | Foster, G. | Coppens, M. | +5

16

Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors

enthalten in: Expert review of hematology | 2023

von Pipe, S. | Dunn, A. | Young, G.

17

Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B

enthalten in: Expert review of hematology | 2023

von Castaman, G. | Coppens, M. | Pipe, S.

18

Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B) : a multicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Haematology | 2023

von Srivastava, A. | Rangarajan, S. | Kavakli, K. | +15

CommentIn: Lancet Haematol. 2023 May;10(5):e308-e309. - PMID 37003277

19

Corrigendum to 'Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis' [Research and Practice in Thrombosis and Haemostasis, Volume 7, Issue 2, February 2023, 100077

enthalten in: Research and practice in thrombosis and haemostasis | 2023

von Pipe, S. | Trzaskoma, B. | Minhas, M. | +7

ErratumFor: Res Pract Thromb Haemost. 2023 Feb 08;7(2):100077. - PMID 36908770

20

Long-Term Effects of Hemophilia B Gene Therapy. Reply

enthalten in: The New England journal of medicine | 2023

von Pipe, S. | Monahan, P.

CommentOn: N Engl J Med. 2023 Feb 23;388(8):706-718. - PMID 36812434